11 Best Genomics Stocks to Buy According to Hedge Funds

7. uniQure N.V. (NASDAQ:QURE)

Number of Hedge Fund Holders: 35

Revenue growth (YoY): 71.17%

Lake Street Capital reiterated its Buy rating and $30 price target for ClearPoint following uniQure N.V. (NASDAQ:QURE) regulatory update on AMT-130, an experimental gene therapy for Huntington’s disease.

uniQure N.V. (NASDAQ:QURE) declared that it has partnered with the FDA to seek an expedited approval process for AMT-130. If the trials go well and the FDA approves it, Lake Street sees AMT-130 as maybe ClearPoint’s first “meaningful partner asset.”

ClearPoint provides disposables valued at almost $20,000 for each AMT-130 infusion, suggesting a significant financial benefit associated with the therapy’s effectiveness. The FDA’s support might result in the approval by the end of 2026, which would have a big effect on ClearPoint’s financial standing and confirm its strategic focus on image-guided neurosurgery and gene therapy delivery.

According to Lake Street, this regulatory milestone increases clarity on ClearPoint’s contribution to the advancement of clinical-stage gene treatments and provides further assurance regarding the clearance timeline for AMT-130.